Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers
Yumi Oh, Hae Rim Jung, Seoyeon Min, Jinjoo Kang, Dongjun Jang, Seungjae Shin, Ji‐Won Kim, Sang Eun Lee, Chang Ohk Sung, Won‐Suk Lee, Charles Lee, Eui Man Jeong, Sung‐Yup Cho
Topics & Concepts
KRASCancer researchPI3K/AKT/mTOR pathwayReactive oxygen speciesIntracellularApoptosisProtein kinase BChemistryDownregulation and upregulationPharmacologyColorectal cancerBiologyCancerBiochemistryGeneGeneticsCell death mechanisms and regulationATP Synthase and ATPases ResearchPARP inhibition in cancer therapy